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This study aimed to evaluate the rate of sustained virological response (SVR) and the clinical and treatment 
characteristics of patients with chronic hepatitis C (CHC). A retrospective uncontrolled cohort study was 
conducted among patients who received treatment for CHC between 2005 and 2008 attended at the Center 
for the Application and Monitoring of Injectable Medications, in Florianopolis, SC, Brazil. The inclusion 
criteria were: patients over 18 years of age, with a confirmed diagnosis of chronic hepatitis C according 
to Brazilian guidelines, treated with PEG-IFN alfa-2a or 2b associated with RBV. A total of 188 patients 
were included in the study: 70% men, 59% genotype 1, 27% coinfected with HIV, 31% with cirrhosis. 
The SVR rate, calculated by probability theory, was determined as 26% (max=57.4% and min=12.8%) 
and the intention to treat was 12.8%. Associations between Sustained Virological Response (SVR) and 
the variables sex (p=0.017), age (p=0.003), genotype (p=0.648) and cirrhosis (p=0.275), were determined 
in the bivariate analysis and only sex and age were significantly associated with SVR. The SVR rate was 
considered low, which can be partially explained by patients’ unfavorable pretreatment characteristics.
Uniterms: Hepatitis C. Hepatitis C Chronic. Effectiveness. Interferon alfa-2a. Interferon alfa-2b.
O objetivo do estudo foi avaliar a taxa de resposta viral sustentada (RVS) e as características clínicas e 
do tratamento dos pacientes portadores de hepatite C crônica. Realizou-se uma coorte retrospectiva não 
controlada com recorte temporal dos anos de 2005 a 2008, dos pacientes atendidos no Polo de Aplicação 
e Monitoramento de Medicamentos Injetáveis, em Florianópolis, SC. Os critérios de inclusão foram: 
pacientes maiores de 18 anos, com diagnóstico confirmado de hepatite C crônica de acordo com o 
protocolo brasileiro, tratados com PEG-IFN alfa-2a ou 2b associado a ribavirina. Total de 188 pacientes 
foi incluído no estudo, 70% homens, 59% genótipo 1, 27% co-infectados com o HIV e 31% apresentando 
cirrose. A taxa de RVS calculada através da teoria das probabilidades foi de 26% (max=57,4% and 
min=12,8%) e por intenção de tratamento de 12,8%. Verificou-se a associação da RVS com as variáveis: 
sexo (p=0,017), idade (p=0,003), genótipo (p=0,648) e presença de cirrose (p=0,275). Somente sexo e 
idade foram associados significativamente com a RVS. A taxa de RVS foi considerada baixa e, em parte, 
pode ser explicada pelas características desfavoráveis dos pacientes para a obtenção de RVS.
Unitermos: Hepatite C. Hepatite C Crônica. Efetividade. Interferona alfa-2a. Interferona alfa-2b.
INTRODUCTION
Estimates indicate that 3% of the world population is 
infected by hepatitis C virus (HCV) and that a significant 
number of people are unaware of their condition as carriers 
of HCV (Alter, 1995; Shepard, Finelli, 2005). Treatment 
of hepatitis C is based on the association of interferon alfa 
(INF) and ribavirin (RBV) or peginterferon alfa (PEG-
IFN) and RBV (Brazil, 2007; National Institute for Health 
and Clinical Excellence, 2006; NIH, 2002). Treatment 
aims to halt the progression of liver disease by inhibit-
ing viral replication. Reduction in hepatic inflammatory 
activity tends to prevent progression to cirrhosis and he-
patocellular carcinoma (National Institute for Health and 
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Clinical Excellence, 2006; NIH, 2002). The incidence of 
adverse effects during treatment reduces patient quality 
of life, while sustained virological response (SVR) to 
treatment seems to improve patient quality of life (Blatt 
et al., 2009). A systematic review comparing the quality 
of life in patients who presented SVR and those who did 
not indicated that quality of life is worse in patients who 
do not achieve SVR (Spiegel et al., 2005).
In the early 1990s, IFN applied three times a week 
was the only therapeutic option for treatment of hepatitis 
C and SVR rates were low, ranging between 5 and 20% 
(Poynard et al., 1996). Currently, therapeutic success is 
achieved in about 40 to 80% of patients using a combina-
tion of IFN and RBV or PEG-IFN and RBV, depending 
on host and viral factors (Fried et al., 2002; Hadziyannis 
et al., 2004; Shepherd et al., 2007; Manns et al., 2001).
Despite the findings of clinical trials, the results of 
effectiveness in Brazil remain below expectations. In a 
study conducted in Rio Grande do Sul involving patients 
with genotype 1 treated with PEG-IFN and RBV, the SVR 
rate was 35.3% (Almeida et al., 2009). In another study 
conducted in Rio de Janeiro, the SVR rate with the use of 
PEG-IFN and RBV in naive patients was 53.0%, including 
all genotypes (Brandão et al., 2006). In studies conducted 
in São Paulo, the SVR rate with the use of PEG-IFN 
and RBV in naive patients with genotype 1 varies from 
42.5% to 51.7% (Narciso-Schiavon et al., 2010; Silva et 
al., 2007).
One of the main factors associated with low thera-
peutic effectiveness of hepatitis C treatment is the high 
incidence of adverse effects that reduce the quality of life 
of patients, which often leads to discontinuation (Fried, 
Hadziyannis, 2004). The most common adverse events 
reported for PEG-IFN and RBV are muscular pain, fatigue, 
anemia, leukopenia, thrombocytopenia and depression 
(Fried, Hadziyannis, 2004; Mulhall, Younossi, 2008; Na-
tional Institute for Health and Clinical Excellence, 2006; 
NIH, 2002).
Monitoring the response to treatment is achieved 
through molecular biology techniques (qualitative and 
quantitative HCV-RNA) at week four of treatment (rapid 
virological response, RVR), at week 12 of treatment (early 
virological response, EVR), at the end of treatment (end of 
treatment response, ETVR) and 24 weeks after complet-
ing treatment (SVR). The expected outcome of treatment, 
currently considered as cure, is the achievement of SVR, 
which is considered the maintenance of negative HCV 
RNA by qualitative PCR six months after the end of treat-
ment (Fried, Hadziyannis, 2004; Mulhall, Younossi, 2008; 
National Institute for Health and Clinical Excellence, 
2006; NIH, 2002).
Several factors can influence the results of hepatitis 
C treatment and may be associated with the therapy (treat-
ment, dose and duration), the virus (genotype, viral load 
before treatment, resistant strains of HCV, cirrhosis) and 
the patient (sex, age, Human immunodeficiency virus 
(HIV), Hepatitis B virus (HBV), obesity, compliance) 
(Fried, Hadziyannis, 2004; Mulhall, Younossi, 2008; Na-
tional Institute for Health and Clinical Excellence, 2006; 
NIH, 2002).
In Brazil, the medications IFN, PEG-IFN and RBV 
are provided by the National Health Service (Sistema 
Único de Saúde, SUS) through the Specialized Pharma-
ceutical Service Component (Componente Especializado 
da Assistência Farmacêutica, CEAF). The request for 
treatment is individual, according to clinical protocol. 
Moreover, according to this protocol, patients undergoing 
treatment with PEG-IFN must have their weekly doses ap-
plied in assisted treatment clinics or services specifically 
identified for these purposes by State and/or Municipal 
Health Secretaries (Brasil, 2007).
Although access to treatment for hepatitis C is 
guaranteed by the CEAF, currently, a significant number 
of patients still resort to the judicial system to ensure that 
the State provides their medications (Chieffi, Barata, 2009; 
Vieira, 2008).
The objectives of this work were to study the profile 
of patients who received medications for chronic hepatitis 
C treatment from the National Health Service and verify 
the rate of SVR to treatment with PEG-IFN associated 
with RBV.
METHODOLOGY
This is a retrospective uncontrolled cohort study 
conducted on patients who received treatment with 
PEG-IFN in association with RBV from January 2005 to 
December 2008 at the Polo de Aplicação e Monitoramento 
de Medicamentos Injetáveis do Hospital Nereu Ramos 
(PAMMI/HNR), Florianópolis, SC, Brazil.
The inclusion criteria were: patients over 18 years 
of age, with a confirmed diagnosis of chronic hepatitis 
C according Brazilian guidelines, treated with PEG-IFN 
alfa-2a or 2b associated with RBV, who were administered 
the medication at the PAMMI/HNR. The exclusion criteria 
were: patients aged less than 18 years old, those who re-
fused to join the study, monotherapy and acute hepatitis C.
Data were collected from patient records and the 
variables considered were: patient characteristics, clinical 
and laboratory data and data related to treatment. These 
categories are described separately in the results.
The variables analyzed were: sex, age, degree of 
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fibrosis, viral genotype, presence of HIV coinfection, 
presence of coinfection with HBV, type of PEG-IFN used, 
prescription origin (public or private), form of access to 
medications (administrative or lawsuit), retreatment, type 
of first treatment, treatment conclusion, ETVR and SRV, 
grouped as variables related to treatment.
The laboratory exam data were obtained from exam 
reports or patient records.
Patients were classified according to liver biopsies, 
into two groups: non-cirrhotic and cirrhotic. The presence 
of cirrhosis was based on a score of fibrosis grade 4 (F4) 
according to the Metavir group scoring system and con-
clusive reports of cirrhosis according to the classification 
of the Brazilian Society of Pathology.
For patients with a virus genotype other than 1, the 
ETVR was considered to be negative PCR results obtained 
24 weeks after the onset of treatment and for genotype 1, 
after 48 weeks. SVR was considered the maintenance of 
negative HCV RNA by qualitative PCR 24 weeks after the 
end of treatment. SVR was calculated using the theory of 
probabilities and by intention to treat.
Data were double entered into a database built on 
Epi date 3.1 and later analyzed using Epi Info software, 
version 3.5.1.
The variables were analyzed by descriptive statistics 
and associations between predictor variables and SVR 
were determined by the Chi square test, with P< 0.05 
considered statistically significant.
The study was approved by the Ethics Committee 
on Human Research of the Federal University of Santa 
Catarina, protocol no. 304/2006.
RESULTS
A total of 211 patients received treatment during the 
period studied. Thirty-one patients were excluded from 
the study because they had acute hepatitis C or they used 
PEG-IFN monotherapy or they began their treatment at 
home. The sample included 188 patients.
Regarding patient characteristics, 70% were male, 
80% aged over 40 years-old and 96% were white, while 
among the risk factors for hepatitis C, the principal factors 
identified were blood transfusion (26%) and injectable 
drug use (22%) (Table I).
The clinical and laboratory characteristics evalu-
ated in the study are presented in Table II. Data from 128 
biopsies were retrieved (62 results were determined using 
the Metavir Classification and 66 by the classification 
of the Brazilian Society of Pathology), with 31% of the 
samples presenting conclusive reports of cirrhosis. In ad-
dition, 59% of patients presented genotype 1, 27% were 
TABLE I - Characterization according to sex, age, race and 
HCV exposure route of patients receiving treatment for chronic 
hepatitis C at the PAMMI/HNR between 2005 and 2008
Variable % (N=188)
Sex
Male 70
Age 
≥ 40 years old 80
Race
White 96
Risk factor
Blood transfusion 26
Injectable drug use 22
Sexual relations 5
Reusable syringes and/or needles 4
Surgical procedure 3
Occupational exposure 3
Unknown route 20
Information not available 17
TABLE II - Clinical parameters prior to treatment of patients 
receiving treatment for chronic hepatitis C at the PAMMI/HNR 
between 2005 and 2008
Variable % (N=188)
Liver histology 
Cirrhotic 31
Non-cirrhotic 37
Information not available 32
Genotype
Genotype 1 59
Genotype 2 4
Genotype 3 1
Genotype 4 2
Genotype 5 1
Information not available 33
Comorbidity
Coinfection with HIV 27
Coinfection with HBV 2
coinfected with HIV and 2% were coinfected with HBV.
Table III presents data regarding treatment with 
PEG-IFN and RBV: 143 patients (76%) received PEG-IFN 
alfa-2a (180 mcg) and 45 patients (24%) received PEG-
IFN alfa-2b (1.5 mg/kg). Thirty-four (18%) patients were 
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receiving retreatment and of these, 94% had been previ-
ously treated with IFN associated with RBV.
Regarding access, 46% of patients had prescriptions 
from private consultations and most received medication 
through the CEAF of the Public Health Service (74%), 
while 26% received medication following lawsuits filed 
against the State.
Figure 1 presents a flow chart showing the number 
of patients who received treatment with PEG-IFN in as-
sociation with RBV (n=188), the number of patients who 
concluded complete treatment (n=176), the number of 
medical records located (n=129), the number of patients 
with records of their exams (n=94), the number of patients 
presenting a response at the end of treatment (n=68) and 
the number of patients achieving SVR (n=24).
Among the 129 patients located in the study, seven 
died. When a patient dies during the treatment, their death 
is invariably associated with the treatment; however, the 
causes of death were not investigated, thus is not possible 
to affirm whether their deaths were related to hepatitis C. 
Of the 122 records located, 94 were submitted to at least 
one of the qualitative HCV RNA exams at the end of treat-
ment and/or SVR.
The SVR rate calculated by the theory of probability 
was 26%. Considering the likelihood of all those not lo-
cated and those without records of exams achieving SVR, 
the real rate could be 57.4%; on the other hand, if all these 
patients did not achieve SVR, the rate would have been 
12.8%. The latter is the same value obtained by calculating 
the intention to treat (24/188).
Considering two groups of patients, those naive 
or on retreatment, the SVR rates are 41.9% and 40.0% 
respectively, without significant statistics.
Associations between SVR and the variables sex, 
age, genotype and cirrhosis were determined and only sex 
and age were significantly associated with SVR (Table IV).
DISCUSSION
The demographic characteristics of patients treated 
at the PAMMI/HNR are in agreement with similar Brazil-
ian studies evaluating the efficacy of PEG-IFN (Almeida et 
al., 2009; Brandão et al., 2006; Mourão et al., 2008; Silva 
et al., 2007). As in other studies, male predominance can 
be explained by greater exposure of men to disorders that 
affect health throughout their lives and their resistance 
to seeking preventive medical care (Braz, 2005). In this 
group of patients, the greater percentage of patients aged 
over 40 years old is probably associated with the higher 
TABLE III - Frequency of variables related to access and medical 
treatment of patients receiving treatment for chronic hepatitis C 
at the PAMMI/HNR between 2005 and 2008
Variables % (N=188)
Medication 
Peginterferon alfa 2a 180 mcg 75
Peginterferon alfa 2b 120 mcg 25
Prescription precedence
Not Public Health Service 46
Public Health Service 39
Information not available 15
Access to drugs 
CEAF 74
Lawsuit 26
Retreatment 
Yes 18
No 73
Information not available 9
First treatment type (N=33)
Interferon alfa + ribavirin 94
Peginterferon alfa 2b 180 mcg + ribavirin 3
Others 3
FIGURE 1 - Flow chart with the number of patients who started, 
completed and who obtained a response at the end and the SRV 
of patients receiving treatment for chronic hepatitis C at the 
PAMMI/HNR between 2005 and 2008.
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TABLE IV - Test of association between SVR and predictor 
variables (sex, age, genotype and cirrhosis) of patients receiving 
treatment for chronic hepatitis C at the PAMMI/HNR between 
2005 and 2008
Variables SRV (%) no SRV (%) P
Sex
Male 58.3 85.7 0.017
Female 41.7 14.3
Age
≥ 40 years old 75.0 94.3 0.003
< 40 years old 25.0 5.7
Genotype
1 75.0 80.0 0.648
Not 1 25.0 20.0
Cirrhosis
Present 25.0 31.4 0.275
Absent 75.0 45.7
risk of exposure to the HCV over time (Quaglio et al., 
2003).
Blood transfusion was the route of HCV acquisition 
reported by most patients in the study; however, hepatitis C 
notification data from the Department of Epidemiological 
Surveillance for the period 2002 to 2004 indicate inject-
able drug use as the main route of acquiring the disease 
(Goncalves et al., 2008). It should be emphasized that 
the exposure data collected in this study originates from 
interviews with patients conducted at the onset of treat-
ment and recorded in the medical records. Self-reporting 
is not the most reliable data source and may not reveal the 
true risk factor of exposure, thus justifying the difference 
between these results. Moreover, blood transfusion was the 
main transmission route before 1993 when HCV testing 
was not available.
Although no correlation between SVR and cirrhosis 
was determined in this sample, the significant percentage 
of patients with cirrhosis (30%) could be a complicating 
factor in achieving SVR, since the degree of fibrosis and 
inflammatory activity is indicative of the prognosis of 
patients with chronic HCV infection (Fried, Hadziyannis, 
2004; NICE, 2006; NIH, 2002). 
Brazilian and foreign studies that have investigated 
HCV-HIV coinfection report SVR rates between 25 and 
30% (Alter, 2006; Segurado et al., 2004; Tovo et al., 
2007). A percentage of 27% of patients presenting HCV-
HIV coinfection follows the trend of these studies and the 
presence of this factor is considered poor prognosis for 
achieving SVR.
A number of studies indicate high prevalence of 
genotype 1 in Brazil (Diament, 2007; Perrone et al., 
2008). Since the sample consisted of patients who used 
PEG-IFN, a higher percentage of patients with genotype 
1 was expected. HCV genotype is an important parameter 
in the indication of treatment, given that genotype 1 pres-
ents lower rates of SVR compared with other genotypes, 
which is why patients with genotype 1 are treated for 48 
weeks, while patients with other genotypes are treated 
for 24 weeks (Ferreira, 2007; Fried, Hadziyannis, 2004; 
Shepherd et al., 2007).
Other prognostic factors considered unfavorable for 
achieving SVR include being male, greater age, longer 
duration of infection, alcohol abuse and immunosuppres-
sion (Fried, Hadziyannis, 2004; NICE, 2006; NIH, 2002; 
Shepherd et al., 2007).
Analysis of the data verified that most patients were 
treated with PEG-IFN 2a, which can be partially explained 
by competition and sales teams in the pharmaceutical in-
dustry. Recently, a systematic review of clinical trials com-
pared the two forms of commercially available PEG-IFN. 
In this review, PEG-IFN 2a showed a significant increase 
in the number of patients who presented SVR compared 
to PEG-IFN 2b (47% vs. 41%, RR 1.11, 95%CI 1:04-1:19, 
p=0.004). No significant differences in the presentation of 
adverse effects were verified (Awad et al., 2010).
Observation verified that most patients seek private 
care or healthcare plans for diagnosis and treatment pre-
scription. This is probably because tests like genotyping, 
biopsy, qualitative and quantitative HCV RNA, often 
involve queues when accessed through the Public Health 
Service. In our opinion, this creates a bottleneck of ac-
cess, where patients who subscribe to or can afford private 
healthcare plans have greater access to medications for the 
treatment of hepatitis C.
Approximately one third of the group of patients 
evaluated obtained their medications by means of law-
suits against the State of Santa Catarina, the majority in 
disagreement with the Brazilian clinical protocol, mainly 
for retreatment and for patients presenting coinfection with 
HIV and genotypes other than 1. Such treatments were 
only permitted from September 2007 onward, following 
the publication of the new Brazilian clinical protocol for 
the treatment of chronic hepatitis C (Brasil, 2007).
Only a few well-conducted randomized clinical trials 
have evaluated HCV retreatment using PEG-IFN. Those 
that have report SVR rates between 8 and 26% for patients 
who were previously treated with IFN (Jensen, Marcellin, 
2005; Taliani, Biliotti, 2007). Only two of the 33 patients 
receiving retreatment at the PAMMI/HNR achieved SVR, 
which corresponds to 6.1%, lower than the literature data.
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Of the 188 patients who received treatment, only 
12 did not conclude, indicating a high percentage of con-
clusions compare to others studied conducted in Brazil 
(Almeida et al., 2009; Narciso-Schiavon et al., 2010). 
Certain characteristics verified during the follow-up of 
these patients suggest the reasons for this rate of conclu-
sion, such as the safety of procedures performed in the 
service, weekly follow-up by a qualified team to manage 
the side effects and complications of treatment, and the 
integration and adaptation of patients attending the service 
for about a year.
Only 59 of the 129 patients located were submitted 
to the SVR exam, revealing a lower percentage than ex-
pected. In some cases, these patients reported no interest 
in knowing the treatment outcome.
Given this low percentage of results concerning 
treatment effectiveness, certain assumptions can be made: 
1) the results of these exams are probably being retained 
in physicians’ offices; 2) patients loose the medical reports 
or may not want to remember the feelings that they were 
exposed to during treatment; 3) clinical follow-up is often 
ineffective after treatment.
When comparing the present results (12.8% for in-
tention to treat) with those of international clinical trials, 
the SVR rate obtained is much lower than that reported 
in the literature, with several studies showing results for 
treatment efficacy close to 50% (Awad et al., 2010; Fried 
et al., 2002; Fried, Hadziyannis, 2004; Manns et al., 2001; 
et al., 2004; Mchutchison, Sulkowski, 2008; Poynard 
et al., 1996), thus reflecting problems in routine patient 
care in Brazilian services. In clinical trials, patients are 
selected by strict inclusion criteria and are attended in a 
standardized and differentiated manner, which in practice 
is not possible, because the services are often undersized 
in terms of infrastructure and human resources in relation 
to the existing demand.
Patients in the group analyzed presented clinical char-
acteristics predictive of a lower rate of SVR (genotype 1, 
male, aged over 40 years old and the presence of cirrhosis), 
although only age and sex were statistically significant.
Higher SVR rates were observed in patients younger 
than 40 years of age, as demonstrated in another study 
(Lindsay et al., 2001). The association between sex and 
SVR was significant, in disagreement with another study 
conducted in Brazil (Narciso-Schiavon et al., 2010). In 
this study, the presence of cirrhosis was not significantly 
associated with SVR, even though the currently accepted 
hypothesis is that the smaller the degree of fibrosis, the 
higher the SVR rates for treatment (Poynard et al., 2000).
When evaluating the findings of this study, certain 
observations should be considered. The study involved 
patients from different municipalities in the greater Flori-
anópolis area and the patients were clinically followed in 
both public health services and private clinics, thus, pos-
sible differences between clinical follow-up, performance 
of exams and consultation procedures may exist. The 
biopsies and laboratory exams were performed in several 
laboratories, possibly using different methodologies. No 
analysis regarding the standardization of ribavirin given 
to patients during treatment was performed and at any 
given moment of treatment, patients may have received 
different brands, because State legislation requires bidding 
processes for all acquisitions and the health service where 
the patients were attended made no record of the brand or 
manufacturer.
Moreover, the study revealed a significant loss of 
data regarding the outcomes evaluated, since almost half 
of the patients had no results verifying SVR status. We 
attempted to correct for this loss of data using probability 
calculations, thus extending the proportions for patients 
not located and those who no longer had or were not sub-
mitted to the required exams.
This absence of data indicates the need for adequate 
health services for full implementation of assistance 
activities. Hepatitis C is a disease requiring notification 
and treatment outcome must form part of the surveillance 
activities of the National Health Program for the Preven-
tion and Control of Viral Hepatitis. 
Moreover, the lack of response to treatment or the 
failure to achieve SVR constitutes yet another problem 
for the Brazilian National Health Service because the 
treatment is being provided could be ineffective or not 
achieving the expected response rates. Patients who did 
not respond to treatment remain a potential source of new 
infections, remain exposed to the risk of aggravation of 
the disease and could evolve to liver failure. 
The participation of pharmacists in collecting and 
analyzing the data permitted a clearer understanding of 
the reality of proposing pharmacotherapeutic follow-up.
CONCLUSIONS
In the group studied, the rate of discontinued treat-
ment was low compared to other studies. However, both 
the SVR rate calculated by the theory of probability of 
26% and by intention to treat of 12.8% are considered 
low values for the outcome of treatment of hepatitis C 
with peginterferon alfa combined with ribavirin. This 
result may be related to the demographic and clinical 
characteristics of the patients studied, considered a “poor 
prognosis group”.
Sustained virological response to treatment of chronic hepatitis C with peginterferon alfa and ribavirin 199
CONFLICT OF INTEREST
The authors declare that there are no conflicts of 
interest.
FINANCIAL SUPPORT
Edict for research projects and technological devel-
opments of priority for the National Unified Health System 
(SUS), MS/CNPq/FAPESC/SES - 008/2006.
Consultancy for the elaboration of research, evalu-
ation and systematization of information to support the 
Pharmacy Therapeutic Commission and the development 
of the Therapeutic Protocol of the DIAF/SES-SC.
REFERENCES
ALMEIDA, P.R.L.; MATTOS, A.A.; AMARAL, K.M; 
FELTRIN, P.Z.; TOVO, C.V.; PICON, P.D. Treatment of 
hepatitis C with peginterferon and ribavirin in a Public 
Health Program. Hepato-gastroenterol., v.56, p.223-226, 
2009.
ALTER, M.J. Epidemiology of hepatitis C in the West. Semin. 
Liver. Dis., v.15, p.5-14, 1995.
ALTER, M.J. Epidemiology of viral hepatitis and HIV co-
infection. J. Hepatol., v.44, p.6-9, 2006.
ANDRADE,  T.U. ;  BURINI,  D.M.;  MELLO,  M.O. ; 
BERSÁCULA, N.S.; SALIBA, R.A.D.; BRAVIM, F.T.; 
BISSOLI, N.S. Evaluation of the satisfaction level of 
patients attended by a Pharmaceutical Care Program in a 
Private Communitarian Pharmacy in Vitória (ES, Brazil). 
Braz. J. Pharm. Sci., v.45, p.349-355, 2009.
AWAD, T.; THORLUND, K.; HAUSER, G.; STIMAC, D.; 
MABROUK, M.; GLUUD, C. Peginterferon alpha-2a is 
associated with higher sustained virological response than 
peginterferon alfa-2b in chronic hepatitis C: Systematic 
review of randomized trials. Hepatology, v.51, n.4, p.1176-
1184, 2010.
BLATT, C.R.; ROSA, J.A.; SANDER, G.; FARIAS, M.R. 
Tratamento da hepatite C e qualidade de vida. Rev. Bras. 
Farm., v.90, p.19-26, 2009.
BRANDÃO, C.; BARONE, A.; CARRILHO, A.; SILVA, 
M.; PATELLI, M.; CARAMORI, C.; FOCACCIA, R.; 
PEREIRA, L.; PEDROSO, M.; TATSCH, F.; PESSOA, 
M. The results of a randomized trial looking at 24 weeks 
VS 48 weeks of treatment with peginterferon a-2a (40 kDa) 
and ribavirin combination therapy in patients with chronic 
hepatitis C genotype 1. J. Viral Hepat., v.13, p.552-559, 
2006.
BRASIL. Ministério da Saúde. Secretaria de Vigilância em 
Saúde. SAS/MS Portaria nº. 34, de 23 set. 2007. Dispõe 
sobre Protocolo Clínico e Diretrizes Terapêuticas para 
Hepatite Viral C. Brasília, DF: Ministério da Saúde, 2007. 
28 set. p.60.
BRAZ, M.A. A construção da subjetividade masculina e seu 
impacto sobre a saúde do homem: reflexão bioética sobre a 
saúde do homem: reflexão bioética sobre saúde distributiva. 
Ciênc. Saúde Colet., v.10, p.97-104, 2005.
CHIEFFI, A.L.; BARATA, R.B. Judicialização da política 
pública de assistência farmacêutica e eqüidade. Cad. Saúde 
Pública, v.25, n.8, p.1839-1849, 2005.
CORRER, C.J.;  PONTAROLO, R.;  SOUZA, R.A.P.; 
VENSON, R.; MELCHIORS, A.C.; WIENS, A. Effect 
of a Pharmaceutical Care Program on quality of life and 
satisfaction with pharmacy services in patients with type 
2 diabetes mellitus. Braz. J. Pharm. Sci., v.45, p.809-817, 
2009.
DIAMENT, D. Epidemiological aspects of hepatitis C in Brazil. 
Braz. J. Infect. Dis., v.11, n.5, suppl. 1, p.6-7, 2007.
FERREIRA, M.S. Treatment of chronic hepatitis C in treatment-
naïve patients. Braz. J. Infect. Dis., v.11, n.5, suppl.1, 
p.45-49, 2007.
FRIED, M.W.; HADZIYANNIS, S.J. Treatment of chronic 
hepatitis C infection with peginterferons plus ribavirin. 
Semin. Liver Dis., v.24, suppl.2, p.47-54, 2004.
FRIED, M.W.; SHIFFMAN, M.L.; REDDY, K.R.; SMITH, C.; 
MARINOS, G.; GONÇALES, F.L.J.; HAUSSINGER, D.; 
DIAGO, M.; CAROSI, G.; DHUMEAUX, D.; CRAXI, A.; 
LIN, A.; HOFFMAN, J.; YU, J. Peginterferon alfa-2a plus 
ribavirin for chronic hepatitis C virus infection. N. Engl. J. 
Med., v.347, p.975-982, 2002.
J. A. Rosa, C. R. Blatt, K. C. Peres, B. H. Storb, R. Silva, M. R. Farias200
GONÇALVES, S.; DAMINELLI, E.N.; SPADA, C.; HAAS, 
P. Panorama da hepatite C no estado de Santa Catarina e 
na cidade de Florianópolis. Rev. Bras. Anal. Clin., v.40, 
p.57-60, 2008.
HADZIYANNIS, S.J.; SETTE, H.J.; MORGAN, T.R.; BALAN, 
V.; DIAGO, M.; MARCELLIN, P.; RAMADORI, G.; 
BODENHEIMER JR., H.; BERNSTEIN, D.; RIZZETTO, 
M.; ZEUZEM, S.; POCKROS, P.J. Peginterferon-alpha2a 
and ribavirin combination therapy in chronic hepatitis C: a 
randomized study of treatment duration and ribavirin dose. 
Ann. Intern. Med., v.140, p.346-355, 2004.
JENSEN, D.M.; MARCELLIN, P. Rationale and design of 
the REPEAT study: a phase III, randomized, clinical trial 
of peginterferon alfa-2a (40 kDa) plus ribavirin in non-
responders to peginterferon alfa-2b (12 kDa) plus ribavirin. 
Eur. J. Gastroenterol. Hepatol., v.17, p.899-904, 2005.
LINDSAY, Y.K.L.; TREPO, C.; HEINTGES, T.; SHIFFMAN, 
M.L.; GORDON, S.C.; HOEFS, J.C.; SCHIFF, E.R.; 
GOODMAN, Z.D. ;  LAUGHLIN,  M. ;  YAO,  R. ; 
ALBRECHT, K.K. A randomized, double-blind trial 
comparing pegylated interferon alfa-2b to interferon alfa-
2b as initial treatment for chronic hepatitis C. Hepatology, 
v.34, p.395-403, 2001.
MANNS, M.P.; MCHUTCHISON, J.G.; GORDON, S.C.; 
RUSTGI, V.K.; SHIFFMAN, M.; REINDOLLAR, 
R.; GOODMAN, Z.D.; KOURY, K.; LING, M.H.; 
ALBRECHT, J.K. Peginterferon alfa-2b plus ribavirin 
compared with interferon alfa-2b plus ribavirin for initial 
treatment of chronic hepatitis C: a randomised trial. Lancet, 
v.358, p.958-65, 2001.
MCHUTCHISON, J.; SULKOWSKI, M. Scientific rationale 
and study design of the individualized dosing efficacy vs 
flat dosing to assess optimal pegylated interferon therapy 
(IDEAL) trial: determining optimal dosing in patients with 
genotype 1 chronic hepatitis C. J. Viral Hepatitis, v.15, 
p.475-481, 2008.
MOURÃO, L.C.S.; ALVES, L.D.S.; LOPES, J.V.S.J.; NUNES, 
L.C.C.; MEDEIROS, M.G.F. Caracterização da hepatite C 
em pacientes assistidos pelo Programa de Medicamentos 
de Dispensação em caráter excepcional. Rev. Bras. Farm., 
v.89, p.226-229, 2008.
MULHALL, B.P.; YOUNOSSI, Z. Impact of adherence on the 
outcome of antiviral therapy for chronic hepatitis C. J. Clin. 
Gastroenterol., v.8, n.39, suppl.1, p.23-27, 2008.
NARCISO-SCHIAVON, J.L.; SCHIAVON, L.L.; CARVALHO-
FILHO, R.J.; SAMPAIO, J.P.; BATAH, P.N.E.; BARBOSA, 
D.V.; FERRAZ, M.L.G; SILVA, A.E.B. Gender influence 
on treatment of chronic hepatitis C genotype 1. Rev. Soc. 
Bras. Med. Trop., v.43, n.3, p.217-223, 2010.
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL 
EXCELLENCE. PegIFN and ribavirin for the treatment 
of mild chronic hepatitis C. London, 2006. 31 p. (NICE 
technology appraisal guidance, 106).
NIH. Consensus Developmente Program. Management of 
Hepatitis C: 2002. Available at: <http://consensus.nih.go
v/2002/2002HepatitisC2002116html.htm>. Acessed on: 
11th jun. 2012.
PERRONE, C.; CASTILLO, D.M.; PEREIRA, G.L.; 
CARVALHO, N.O.; JANUARIO, J.N.; TEIXEIRA, R. 
High prevalence of genotype 1 in individuals with hepatitis 
C in Belo Horizonte, MG. Rev. Soc. Bras. Med. Trop., v.41, 
p.238-242, 2008.
POYNARD, T.; LEROY, V.; COHARD, M.; THEVENOT, T.; 
MATHURIN, P.; OPOLON, P. Meta-analysis of interferon 
randomized trials in the treatment of viral hepatitis C: 
effects of dose and duration. Hepatology, v.24, p.778-896, 
1996.
POYNARD, T.; MCHUTCHISON, J.; GOODMAN, Z.; LING, 
M.H.; ALBRECHT, J. Is an “a la carte” combination 
interferon alfa-2b plus ribavirin regimen possible for the 
first line treatment in patients with chronic hepatitis C?. 
Hepatology, v.31, p.211-218, 2000.
QUAGLIO, G.; LUGOBONI, F.; PAJUSCO, B.; SARTI, M.; 
TALAMINI, G.; LECHI, A. et al.. Factors associated with 
hepatitis C virus infection in injection and noninjection 
drug users in Italy. Clin. Infect. Dis., v.37, p.33-40, 2003.
SEGURADO, A.C.; BRAGA, P.; ETZEL, A.; CARDOSO, 
M.R. Hepatitis C virus coinfection in a cohort of HIV-
infected individuals from Santos, Brazil: seroprevalence 
and associated factors. AIDS Patient Care, v.18, p.135-143, 
2004.
SHEPARD, J.; FINELLI, A. Global epidemiology of hepatitis 
C virus infection. Lancet Infect. Dis., v.5, p.558-567, 2005.
Sustained virological response to treatment of chronic hepatitis C with peginterferon alfa and ribavirin 201
SHEPHERD, J.; JONES, J.; HARTWELL, D.; DAVIDSON, 
P.; PRICE, A.; WAUGH, N. IFN (pegylated and non-
pegylated) and ribavirin for the treatment of mild chronic 
hepatitis C: a systematic review and economic evaluation. 
Health Technol. Assess., v.11, p.1-205, 2007.
SILVA, G.F.; POLONIO, R.J.; PARDINI, M.I.M.C.; CORVINO, 
S.M.; HENRIQUES, R.M.S.; PERES, M.N.; SILVEIRA, 
L.V.A.; COELHO, K.I.R. Using Pegylated IFN-2b and 
ribavirin to treat chronic hepatitis patient infected with 
hepatitis C vírus genotype 1: are nonresponders and 
relapsers different populations? Braz. J. Infect. Dis., v.11, 
p.554-560, 2007.
SPIEGEL, B.M.; YOUNOSSI, Z.M.; HAYS, R.D.; REVICKI, 
D.; ROBBINS, S.; KANWAL, F. Impact of hepatitis C 
on health related quality of life: a systematic review and 
quantitative assessment. Hepatology, v.41, p.790-800, 2005.
TALIANI, G.; BILIOTTI, E. Retreatment of chronic hepatitis 
C patients non responder to a previous antiviral treatment. 
Recenti Prog. Med., v.98, p.219-224, 2007.
TOVO, C.V.; MATTOS, A.A.; SOUZA, A.R.; RIGO, J.F.O.; 
ALMEIDA, P.R.L.; GALPERIM, B.; SANTOS, B.R. 
Impact of human immunodeficiency virus infection in 
patients infected with the hepatitis C virus. Liver Int., v.27, 
p.40-46, 2007.
VIEIRA, F.S. Ações judiciais e direito à saúde: reflexão sobre a 
observância aos princípios do SUS. Rev. Saúde Púb., v.42, 
p.365-369, 2008.
WETTERMARK, B.; PERSSON, M.E; WILKING, N.; KALIN, 
M.; KORKMAZ, S.; HJEMDAHL, P.; GODMAN, B.; 
PETZOLD, M.; GUSTAFSSON, L.L. Forecasting drug 
utilization and expenditure in a metropolitan health region. 
BMC Health Serv. Res., v.10, p.1-14, 2010.
Received for publication on 19th April 2011
Accepted for publication on 05th April 2012

